Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment

Jensen, Henrik Boye; Ravnborg, Mads; Mamoei, Sepehr; Dalgas, Ulrik; Stenager, Egon

doi:10.1177/1352458514533844

Cited by 52 publications

(64 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(2014) did not improve in their performance in the 9‐HPT following dalfampridine treatment. Other studies, though, have reported improvements in the 9‐HPT in dalfampridine‐treated patients (Allart et al., 2015; Jensen et al., 2014; Lo et al., 2015; Pavsic et al., 2015) while Savin et al. (2016) detected positive effects of dalfampridine treatment only on the dominant hand.…”

Section: Discussionmentioning

confidence: 99%

“…In line with a number of previous studies, we did observe a beneficial effect of dalfampridine on the cognitive function of MS patients (Jensen et al., 2014; Ruck et al., 2014; Triche, Ruiz, Olson, & Lo, 2016). In our cohort, the improvement of the performance in the PASAT test was independent of the responder status.…”

Section: Discussionmentioning

confidence: 99%

“…However, regarding the assumed effects on conduction, action‐potentials, and synaptic and neuromuscular transmission, it would be very likely that the compound also has an effect on other parts of the central nervous system and therefore on other neurological functions such as vision, fatigue, or cognition (Kim, Goldner, & Sanders, 1980; Shi & Blight, 1997; Smith, Felts, & John, 2000). Indeed, studies investigating whether or not dalfampridine or 4‐aminopyridine exert beneficial effects on other neurological function in MS patients described positive effects on measures of cognitive function, upper limb function, fatigue, and vision (Horton et al., 2013; Jensen, Ravnborg, Mamoei, Dalgas, & Stenager, 2014; Limone, Sidovar, & Coleman, 2013; Magnin et al., 2015; Pavsic, Pelicon, Ledinek, & Sega, 2015; Prugger & Berger, 2013; Rossini et al., 2001; Ruck et al., 2014). …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dalfampridine effects on cognition, fatigue, and dexterity

et al. 2016

View full text Add to dashboard Cite

ObjectivesDalfampridine exerts beneficial effects on walking ability in a subgroup of patients with multiple sclerosis (MS). These patients are termed “responders”. Here, we investigated whether the responder status with respect to mobility measures would determine whether dalfampridine treatment exerts a beneficial effect on other MS symptoms. We therefore assessed walking ability, upper limb function, cognition, fatigue, visual evoked potentials (VEPs), depression, and quality of life in patients before and after dalfampridine treatment.MethodsPatients with MS and impaired mobility were recruited. Maximal walking distance, timed 25 Foot Walk, nine hole peg test, paced auditory serial addition test (PASAT), fatigue severity scale (FSS), VEPs, Beck Depression Inventory (BDI), EuroQol five dimensional questionnaire, and quality of life visual analogue scale were determined before and after 12–14 days of dalfampridine treatment. Repeated measures analysis of variance was applied to determine the effect of dalfampridine treatment.ResultsOf the 34 patients who completed the study, 22 patients were responders and 12 patients nonresponders, according to their performance in mobility measures. Treatment effects for the entire patient cohort were observed for PASAT (p = .029) and BDI (p = .032). Belonging to the responder cohort did not predict the response to treatment in these tests. For the FSS, response to dalfampridine treatment was dependent on the responder status (p = .001) while no effects in the total patient cohort were observed (p = .680). Other neurological functions remained unaltered. For VEP latencies, no significant improvements were detected.ConclusionIn this study, we observed beneficial effects of dalfampridine on cognition, depression, and fatigue. These effects were not limited to patients who responded to dalfampridine with improved mobility measures. These findings underscore the need to assess the beneficial effects of dalfampridine on neurological deficits in MS patients in additional randomized clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dalfampridine effects on cognition, fatigue, and dexterity

et al. 2016

View full text Add to dashboard Cite

show abstract

“…After 26-28 days of treatment, results showed significant improvements on quantitative tests of upper and lower limb functions as well as the SDMT [50].…”

Section: Symptomatic Drugsmentioning

confidence: 92%

Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?

Niccolai

Goretti

Amato

2017

Mult Scler Demyelinating Disord

View full text Add to dashboard Cite

Cognitive dysfunction is frequent in multiple sclerosis patients and has important and negative consequences for daily activities and quality of life of subjects. Disease modifying treatments for multiple sclerosis reduce the incidence of relapses and may prevent disease progression, but the influence on cognitive impairment is unclear, due to several limitations of the available studies. Moreover, symptomatic drugs for the improvement of already established cognitive deficits have been tested in small pilot studies, providing conflicting or mainly negative results. Currently, specific pharmacological therapies for the management of cognitive deficits in MS have not yet been developed. We will provide an updated overview of available evidence of pharmacological approaches for ameliorating cognitive deficits, based either on disease modifying treatments or symptomatic drugs.

show abstract

“…All forms of MS were included (relapsing remitting, primary progressive, secondary progressive) [12]. There were wide variations in terms of age, ranging from 18 to 70 years [8,[13][14][15][16] or from 18 to 60 years [17,18].…”

Section: Choice Of Participantsmentioning

confidence: 99%

Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review

Lecat¹,

Decavel²,

Magnin³

et al. 2017

Eur Neurol

View full text Add to dashboard Cite

Background: Gait impairment is one of the most disabling symptoms in people with multiple sclerosis (PwMS). Fampridine, has demonstrated a positive effect on gait speed in PwMS after 14 days of treatment but the long-term effects have not yet been demonstrated. This study reviews the long-term effects of fampridine on gait in PwMS. Summary: This systematic review was conducted according to the PRIS-MA statement. Studies were considered long term if treatment exceeded 28 days. From the 498 studies identified, 18 (2,200 patients) fulfilled all eligibility criteria. Only 3 studies followed-up patients for >1 year and one of these showed a non-significant improvement in the gait speed. Key Messages: Fampridine seems to be beneficial at improving gait speed in PwMS in the long term. Further long-term studies are needed on related gait and functional parameters.

show abstract

Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment

Abstract: SR Fampridine treatment has significant effects on different domains including upper and lower body and cognition. Furthermore, the SSST is more responsive to the effect of SR Fampridine than is the T25FW. ClinicalTrials.gov identifier: NCT01656148.

Cited by 52 publications

References 38 publications

Dalfampridine effects on cognition, fatigue, and dexterity

Dalfampridine effects on cognition, fatigue, and dexterity

Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?

Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review

Contact Info

Product

Resources

About